Update on Use of Chloroquine/Hydroxychloroquine to Treat Coronavirus Disease 2019 (COVID-19)
et al., Biosci Trends, May 21, 2020, 14:2, 156-158, doi:10.5582/bst.2020.03072, Epub Apr 13, 2020, Apr 2020
HCQ for COVID-19
1st treatment shown to reduce risk in
March 2020, now with p < 0.00000000001 from 424 studies, used in 59 countries.
No treatment is 100% effective. Protocols
combine treatments.
6,300+ studies for
210+ treatments. c19early.org
|
Increasing evidence from completed clinical studies shows CQ and HCQ effective (HCQ more effective).
1.
Mothae et al., SARS-CoV-2 host-pathogen interactome: insights into more players during pathogenesis, Virology, doi:10.1016/j.virol.2025.110607.
2.
Monsalve et al., NETosis: A key player in autoimmunity, COVID-19, and long COVID, Journal of Translational Autoimmunity, doi:10.1016/j.jtauto.2025.100280.
3.
Xie et al., The role of reactive oxygen species in severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection-induced cell death, Cellular & Molecular Biology Letters, doi:10.1186/s11658-024-00659-6.
4.
Gkioulekas et al., Use of hydroxychloroquine in multidrug protocols for SARS-CoV-2, Tasman Medical Journal, 6:4, tasmanmedicaljournal.com/2024/10/use-of-hydroxychloroquine-in-multidrug-protocols-for-sars-cov-2a/.
5.
Gortler et al., Those Published “17,000 Hydroxychloroquine Deaths” Never Happened, Brownstone Journal, brownstone.org/articles/those-published-17000-hydroxychloroquine-deaths-never-happened/.
6.
Boretti et al., Correct Use of HCQ Did Not Cause Extra Fatalities in COVID-19 Infection, Coronaviruses, doi:10.2174/0126667975327612240902104505.
7.
Gortler (B) et al., Trump’s 63 Million Doses of Hydroxychloroquine Could Have Been Great for America, Brownstone Journal, brownstone.org/articles/trumps-63-million-doses-of-hydroxychloroquine-could-have-been-great-for-america/.
8.
Enyeji et al., Effective Treatment of COVID-19 Infection with Repurposed Drugs: Case Reports, Viral Immunology, doi:10.1089/vim.2024.0034.
9.
Asaba et al., Interplay of TLR4 and SARS-CoV-2: Unveiling the Complex Mechanisms of Inflammation and Severity in COVID-19 Infections, Journal of Inflammation Research, doi:10.2147/jir.s474707.
10.
Scheim et al., Back to the Basics of SARS-CoV-2 Biochemistry: Microvascular Occlusive Glycan Bindings Govern Its Morbidities and Inform Therapeutic Responses, Viruses, doi:10.3390/v16040647.
11.
Ali et al., SARS-CoV-2 Syncytium under the Radar: Molecular Insights of the Spike-Induced Syncytia and Potential Strategies to Limit SARS-CoV-2 Replication, Journal of Clinical Medicine, doi:10.3390/jcm12186079.
12.
Brouqui et al., There is no such thing as a Ministry of Truth and why it is important to challenge conventional “wisdom” - A personal view, New Microbes and New Infections, doi:10.1016/j.nmni.2023.101155.
13.
Loo et al., Recent Advances in Inhaled Nanoformulations of Vaccines and Therapeutics Targeting Respiratory Viral Infections, Pharmaceutical Research, doi:10.1007/s11095-023-03520-1.
14.
Boretti (B), A., Pharmacotherapy for Covid-19 infection in the countries of the Cooperation Council for the Arab States, Journal of Taibah University Medical Sciences, doi:10.1016/j.jtumed.2021.08.005.
15.
Vigbedor et al., Review of four major biomolecular target sites for COVID-19 and possible inhibitors as treatment interventions, Journal of Applied Pharmaceutical Science, doi:10.7324/JAPS.2021.110825.
16.
Kaur et al., Folic acid as placebo in controlled clinical trials of hydroxychloroquine prophylaxis in COVID-19: Is it scientifically justifiable?, Medical Hypotheses, doi:10.1016/j.mehy.2021.110539.
17.
Raoult, D., Rational for meta-analysis and randomized treatment: the COVID-19 example, Clinical Microbiology and Infection, doi:10.1016/j.cmi.2020.10.012.
18.
Matada et al., A comprehensive review on the biological interest of quinoline and its derivatives, Bioorganic & Medicinal Chemistry, doi:10.1016/j.bmc.2020.115973.
19.
IHU, Natural history and therapeutic options for COVID-19, Expert Review of Clinical Immunology, www.mediterranee-infection.com/wp-content/uploads/2020/09/ERM-2020-0073.R1_Proof_hi.pdf.
20.
Hecel et al., Zinc(II)—The Overlooked Éminence Grise of Chloroquine’s Fight against COVID-19?, Pharmaceuticals, 13:9, 228, doi:10.3390/ph13090228.
21.
Li et al., Is hydroxychloroquine beneficial for COVID-19 patients?, Cell Death & Disease volume 11, doi:10.1038/s41419-020-2721-8.
22.
Goldstein, L., Hydroxychloroquine-based COVID-19 Treatment, A Systematic Review of Clinical Evidence and Expert Opinion from Physicians’ Surveys, Preprint, July 7, 2020, wattsupwiththat.com/2020/07/07/hydroxychloroquine-based-covid-19-treatment-a-systematic-review-of-clinical-evidence-and-expert-opinion-from-physicians-surveys/.
23.
Roussel et al., Influence of conflicts of interest on public positions in the COVID-19 era, the case of Gilead Sciences, New Microbes and New Infections, Volume 38
, doi:10.1016/j.nmni.2020.100710.
24.
Mo et al., Chloroquine phosphate: therapeutic drug for COVID-19, Journal of Southern Medical University, doi:10.12122/j.issn.1673-4254.2020.04.22.
25.
Gao et al., Update on Use of Chloroquine/Hydroxychloroquine to Treat Coronavirus Disease 2019 (COVID-19), Biosci Trends, May 21, 2020, 14:2, 156-158, doi:10.5582/bst.2020.03072.
26.
Derwand et al., Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today's battle against COVID-19?, Medical Hypotheses, doi:10.1016/j.mehy.2020.109815.
27.
Sahraei et al., Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine, International Journal of Antimicrobial Agents, April 2020, 55:4, doi:10.1016/j.ijantimicag.2020.105945.
28.
Todaro et al., An Effective Treatment for Coronavirus (COVID-19), github.com/covidtrial/info/raw/master/An%20Effective%20Treatment%20for%20Coronavirus%20(COVID-19).pdf.
Gao et al., 13 Apr 2020, peer-reviewed, 2 authors.
Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19)
BioScience Trends, doi:10.5582/bst.2020.03072
Coronavirus disease 2019 has caused more than 1 million confirmed cases and approximately 70,000 deaths worldwide as of April 6, 2020 (1). Drugs that are specifically efficacious against SARS-CoV-2 have yet to be established. Chloroquine and hydroxychloroquine have garnered considerable attention for their potential to treat COVID-19. In China, chloroquine was added to the "Guidance for Corona Virus Disease 2019: Prevention, Control, Diagnosis, and Management" issued by the National Health Commission on February 18, 2020 (2). The U.S. Food and Drug Administration (FDA) issued an emergency use authorization for chloroquine/ hydroxychloroquine to treat COVID-19 on March 28, 2020 (3). The European Medicines Agency contended that the two drugs should be used in clinical trials or national emergency use programs for the treatment of COVID-19 on April 1, 2020 (4). The low cost and easy availability of chloroquine/hydroxychloroquine may help to curb this global public health emergency if their efficacy and safety are ultimately verified in clinical studies. Chloroquine phosphate is the first drug reported to display efficacy against COVID-19 in early clinical studies in China (5, 6) . Based on this encouraging finding, chloroquine phosphate was added to the Sixth Edition of the Guidance for tentative treatment of . The Sixth Edition recommended that adult patients in whom chloroquine is not contraindicated should take chloroquine phosphate tablets, 500 mg (300 mg for chloroquine) twice a day for no more than 10 days (7). To reduce the risk of adverse effects of chloroquine, the Seventh Edition of the Guidance, issued on March 3, 2020, recommends a reduced dosage and shortened
References
Chen, Hu, Zhang, Jiang, Han et al., Efficacy of hydroxychloroquine in patients with COVID-19: Results of a randomized clinical trial, medRxiv, doi:10.1101/2020.03.22.20040758
Chen, Liu, Liu, Xu, Xia et al., A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19
Gao, Tian, Yang, Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci Trends
Gautret, Lagier, Parola, Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin
Gautret, Lagier, Parola, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105949
Huang, Tang, Pang, Treating COVID-19 with Chloroquine, J Mol Cell Biol
Lenzer, Covid-19: US gives emergency approval to hydroxychloroquine despite lack of evidence, BMJ
Liu, Cao, Xu, Wang, Zhang et al., Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study, Lancet
DOI record:
{
"DOI": "10.5582/bst.2020.03072",
"ISSN": [
"1881-7815",
"1881-7823"
],
"URL": "http://dx.doi.org/10.5582/bst.2020.03072",
"author": [
{
"affiliation": [
{
"name": "Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, China."
}
],
"family": "Gao",
"given": "Jianjun",
"sequence": "first"
},
{
"affiliation": [
{
"name": "Department of Pathology, the Affiliated Hospital of Qingdao University, Qingdao, China."
}
],
"family": "Hu",
"given": "Shasha",
"sequence": "additional"
}
],
"container-title": "BioScience Trends",
"container-title-short": "BST",
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2020,
4,
12
]
],
"date-time": "2020-04-12T22:03:57Z",
"timestamp": 1586729037000
},
"deposited": {
"date-parts": [
[
2020,
5,
23
]
],
"date-time": "2020-05-23T03:39:35Z",
"timestamp": 1590205175000
},
"indexed": {
"date-parts": [
[
2024,
5,
7
]
],
"date-time": "2024-05-07T11:14:47Z",
"timestamp": 1715080487012
},
"is-referenced-by-count": 39,
"issue": "2",
"issued": {
"date-parts": [
[
2020,
4,
30
]
]
},
"journal-issue": {
"issue": "2",
"published-print": {
"date-parts": [
[
2020
]
]
}
},
"language": "en",
"link": [
{
"URL": "https://www.jstage.jst.go.jp/article/bst/14/2/14_2020.03072/_pdf",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "3542",
"original-title": [],
"page": "156-158",
"prefix": "10.5582",
"published": {
"date-parts": [
[
2020,
4,
30
]
]
},
"published-print": {
"date-parts": [
[
2020,
4,
30
]
]
},
"publisher": "International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)",
"reference": [
{
"key": "1",
"unstructured": "1. COVID-19 Map. <i>https://coronavirus.jhu.edu/map.html </i>(accessed April 6, 2020)."
},
{
"key": "2",
"unstructured": "2. National Health Commission. Interpretation of the Sixth Edition of the Guidance for COVID-19: Prevention, Control, Diagnosis, and Management. <i>http://www.nhc.gov.cn/xcs/fkdt/202002/54e1ad5c2aac45c19eb541799bf637e9.shtml</i> (accessed April 2, 2020). (in Chinese)"
},
{
"DOI": "10.1136/bmj.m1335",
"doi-asserted-by": "crossref",
"key": "3",
"unstructured": "3. Lenzer J. Covid-19: US gives emergency approval to hydroxychloroquine despite lack of evidence. BMJ. 2020; 369:m1335."
},
{
"key": "4",
"unstructured": "4. COVID-19: chloroquine and hydroxychloroquine only to be used in clinical trials or emergency use programmes. European Medicines Agency. <i>https://www.ema.europa.eu/en/documents/press-release/covid-19-chloroquine-hydroxychloroquine-only-be-used-clinical-trials-emergency-use-programmes_en.pdf</i> (accessed April 6, 2020)."
},
{
"key": "5",
"unstructured": "5. The Multicenter Collaboration Group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for Chloroquine in the Treatment of Novel Coronavirus Pneumonia. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 2020; 43:E019. (in Chinese)"
},
{
"DOI": "10.5582/bst.2020.01047",
"doi-asserted-by": "crossref",
"key": "6",
"unstructured": "6. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020; 14:72-73."
},
{
"key": "7",
"unstructured": "7. Notice on Issuance of the Sixth Edition of the Guidance for COVID-19: Prevention, Control, Diagnosis, and Management. National Health Commission. <i>http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2.shtml</i> (accessed April 2, 2020). (in Chinese)"
},
{
"key": "8",
"unstructured": "8. Notice on Issuance of the Seventh Edition of the Guidance for COVID-19: Prevention, Control, Diagnosis, and Management. National Health Commission. <i>http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml</i> (Accessed April 2, 2020). (in Chinese)"
},
{
"key": "9",
"unstructured": "9. National Health Commission. Audio transcript of a news briefing held by the State Council of China on March 17, 2020. <i>http://www.nhc.gov.cn/xcs/fkdt/202003/01426fc0590249ecac89a2874214e523.shtml</i> (accessed April 6, 2020). (in Chinese)"
},
{
"DOI": "10.1093/jmcb/mjaa014",
"doi-asserted-by": "crossref",
"key": "10",
"unstructured": "10. Huang M, Tang T, Pang P, <i>et al</i>. Treating COVID-19 with Chloroquine. J Mol Cell Biol. 2020."
},
{
"key": "11",
"unstructured": "11. International meeting to share experiences to prevent and control COVID-19. <i>https://e.dxy.cn/broadcast/live/id/13818?source=pagesidebar</i> (Accessed April 8, 2020)."
},
{
"DOI": "10.1038/s41421-020-0156-0",
"doi-asserted-by": "crossref",
"key": "12",
"unstructured": "12. Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, Li Y, Hu Z, Zhong W, Wang M. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection <i>in vitro</i>. Cell Discov. 2020; 6:16."
},
{
"DOI": "10.1016/j.ijantimicag.2020.105949",
"doi-asserted-by": "crossref",
"key": "13",
"unstructured": "13. Gautret P, Lagier JC, Parola P, <i>et al</i>. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;105949. DOI: 10.1016/j.ijantimicag.2020.105949."
},
{
"key": "14",
"unstructured": "14. Gautret P, Lagier JC, Parola P, <i>et al</i>. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: An observational study. Méditerranée Infection. 2020. <i>https://www.mediterranee-infection.com/wp-content/uploads/2020/03/COVID-IHU-2-1.pdf </i>(accessed April 6, 2020)."
},
{
"DOI": "10.1016/S0140-6736(20)30566-3",
"doi-asserted-by": "crossref",
"key": "15",
"unstructured": "15. Zhou F, Yu T, Du R, <i>et al</i>. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020; 395:1054-1062."
},
{
"DOI": "10.1101/2020.03.22.20040758",
"doi-asserted-by": "crossref",
"key": "16",
"unstructured": "16. Chen ZW, Hu JJ, Zhang ZW, Jiang S, Han SM, Yan DD, Zhuang RH, Hu B, Zhang Z. Efficacy of hydroxychloroquine in patients with COVID-19: Results of a randomized clinical trial. medRxiv. 2020; doi: https://doi.org/10.1101/2020.03.22.20040758."
},
{
"key": "17",
"unstructured": "17. Chen J, Liu DP, Liu L, Xu QN, Xia L, Ling Y, Huang D, Song SL, Zhang DD, Qian ZP, Li T, Shen YZ, Lu HZ. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). Zhe Jiang Da Xue Xue Bao. 2020. (in Chinese)."
}
],
"reference-count": 17,
"references-count": 17,
"relation": {},
"resource": {
"primary": {
"URL": "https://www.jstage.jst.go.jp/article/bst/14/2/14_2020.03072/_article"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [],
"subtitle": [],
"title": "Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19)",
"type": "journal-article",
"volume": "14"
}